The UK biotech Emergex Vaccines has raised over €9.9M in a Series A funding round, which will allow it to progress the development of vaccines against diseases such as dengue, influenza, and Ebola to phase I clinical trials. Emergex specializes in the development of ‘set-point’ vaccines, which company CEO and co-founder Thomas Rademacher describes as vaccines that convert potentially lethal infections into mild infections that stimulate the body to become immune to the disease in question. Source: Labiotech 9/1/2020